ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

UPI (MM)

1.20
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:UPI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.20 0 01:00:00

Uroplasty to Participate in the 27th Annual ROTH Conference

27/02/2015 12:00pm

PR Newswire (US)


(MM) (NASDAQ:UPI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more (MM) Charts.

MINNEAPOLIS, Feb. 27, 2015 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that it will participate in the 27th Annual ROTH Conference on Tuesday, March 10, 2015. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 4:00 p.m. Pacific Time and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.

Attendance at the conference is by invitation only. A live webcast of the presentation with accompanying slides will be broadcast via the Internet. Those interested in joining the webcast may access it through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days following the event.

About Uroplasty
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Uroplasty's focus is the continued commercialization of its Urgent® PC Neuromodulation System, which Uroplasty believes is the only commercially available, FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults.  The symptoms include urinary urgency, frequency and urge incontinence.  Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Uroplasty and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

Brett Reynolds, SVP and CFO

952-426-6152

 

EVC Group

Doug Sherk/Brian Moore (Investors)

415-652-9100/310-579-6199

Janine McCargo (Media)

646-688-0425

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uroplasty-to-participate-in-the-27th-annual-roth-conference-300042614.html

SOURCE Uroplasty, Inc.

Copyright 2015 PR Newswire

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock